{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:50:45Z","timestamp":1784335845107,"version":"3.55.0"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medtronic"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy. The aim of this study was to evaluate the cost-effectiveness of first-line cryoablation compared with first-line AADs for treating symptomatic PAF in an English National Health Service (NHS) setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Individual patient-level data from 703 participants with PAF enrolled into Cryo-FIRST (Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation), STOP AF First (Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation) and EARLY-AF (Early Aggressive Invasive Intervention for Atrial Fibrillation) were used to derive the parameters applied in the cost-effectiveness model (CEM). The CEM comprised a hybrid decision tree and Markov structure. The decision tree had a 1-year time horizon and was used to inform the initial health state allocation in the first cycle of the Markov model (40-year time horizon; 3-month cycle length). Health benefits were expressed in quality-adjusted life years (QALYs). Costs and benefits were discounted at 3.5% per year. Model outcomes were generated using probabilistic sensitivity analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The results estimated that cryoablation would yield more QALYs (+0.17) and higher costs (+\u00a3641) per patient over a lifetime than AADs. This produced an incremental cost-effectiveness ratio of \u00a33783 per QALY gained. Independent of initial treatment, individuals were expected to receive ~1.2 ablations over a lifetime. There was a 45% relative reduction in time spent in AF health states for those initially treated with cryoablation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>AF rhythm control with first-line cryoablation is cost effective compared with first-line AADs in an English NHS setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2023-002423","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T06:45:31Z","timestamp":1705560331000},"page":"e002423","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English National Health Service perspective"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01803438","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03118518","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02825979","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01803438","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03118518","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02825979","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0220-0343","authenticated-orcid":false,"given":"John","family":"Paisey","sequence":"first","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Moss","sequence":"additional","affiliation":[{"name":"York Health Economics Consortium, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-5123","authenticated-orcid":false,"given":"Jason","family":"Andrade","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kuniss","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Wazni","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Battista","family":"Chierchia","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[{"name":"York Health Economics Consortium, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Ismyrloglou","sequence":"additional","affiliation":[{"name":"Medtronic Bakken Research Center BV, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sale","sequence":"additional","affiliation":[{"name":"Medtronic, Mounds View, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Souter","sequence":"additional","affiliation":[{"name":"Medtronic Limited, Watford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Kaplon","sequence":"additional","affiliation":[{"name":"Medtronic, Mounds View, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bromilow","sequence":"additional","affiliation":[{"name":"York Health Economics Consortium, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lane","sequence":"additional","affiliation":[{"name":"York Health Economics Consortium, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Lewis","sequence":"additional","affiliation":[{"name":"York Health Economics Consortium, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derick","family":"Todd","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Liverpool Heart & Chest Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"2025081711032916000_11.1.e002423.1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/pace.13356","article-title":"Atrial fibrillation symptom profiles associated with Healthcare utilization: A latent class regression analysis","volume":"41","author":"Streur","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025081711032916000_11.1.e002423.2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317715769"},{"key":"2025081711032916000_11.1.e002423.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k1717","article-title":"Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. Bmj","volume":"361","author":"Adderley","year":"2018","journal-title":"BMJ"},{"key":"2025081711032916000_11.1.e002423.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.09.036"},{"key":"2025081711032916000_11.1.e002423.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-020-01396-w","article-title":"Psychological aspects of atrial fibrillation: A systematic narrative review: impact on incidence, cognition, prognosis, and symptom perception","volume":"22","author":"Ladwig","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2025081711032916000_11.1.e002423.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226730","article-title":"Health-related quality of life in patients with atrial fibrillation: the role of symptoms, Comorbidities, and the type of atrial fibrillation","volume":"14","author":"Witassek","year":"2019","journal-title":"PLoS One"},{"key":"2025081711032916000_11.1.e002423.7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","article-title":"Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs","volume":"8","author":"Burdett","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025081711032916000_11.1.e002423.8","unstructured":"National Institute for Health and Care Excellence . NICE guideline Ng196 (atrial fibrillation: diagnosis and management). 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng196\/evidence\/full-guideline-pdf-9081927326"},{"key":"2025081711032916000_11.1.e002423.9","unstructured":"The National Institute for Cardiovascular Outcomes Research . National audit of cardiac rhythm managment: 2021 summary report. 2021. Available: https:\/\/www.nicor.org.uk\/wp-content\/uploads\/2021\/10\/NACRM-Domain-Report_2021_FINAL.pdf"},{"key":"2025081711032916000_11.1.e002423.10","unstructured":"National Institute for Health and Care Excellence . Interventional procedures guidance Ipg427 (percutaneous balloon Cryoablation for pulmonary vein isolation in atrial fibrillation). 2012. Available: https:\/\/www.nice.org.uk\/guidance\/ipg427"},{"key":"2025081711032916000_11.1.e002423.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw285"},{"key":"2025081711032916000_11.1.e002423.12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with Paroxysmal atrial fibrillation","volume":"23","author":"Kuniss","year":"2021","journal-title":"EP Europace"},{"key":"2025081711032916000_11.1.e002423.13","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081711032916000_11.1.e002423.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029980"},{"key":"2025081711032916000_11.1.e002423.15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/europace\/eut380","article-title":"Cost-effectiveness of Cryoballoon ablation for the management of Paroxysmal atrial fibrillation","volume":"16","author":"Reynolds","year":"2014","journal-title":"EP Europace"},{"key":"2025081711032916000_11.1.e002423.16","unstructured":"R Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2022. Available: https:\/\/www.R-project.org"},{"key":"2025081711032916000_11.1.e002423.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"2025081711032916000_11.1.e002423.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.05.012"},{"key":"2025081711032916000_11.1.e002423.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2025081711032916000_11.1.e002423.20","unstructured":"National Institute for Health and Care Excellence . Guide to the methods of technology appraisal (section 5.6.1) [Pmg9]. 2013. Available: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword"},{"key":"2025081711032916000_11.1.e002423.21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/europace\/eux217","article-title":"The influence of progression of atrial fibrillation on quality of life: a report from the Euro heart survey","volume":"20","author":"Dudink","year":"2018","journal-title":"EP Europace"},{"key":"2025081711032916000_11.1.e002423.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019422"},{"key":"2025081711032916000_11.1.e002423.23","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad051","article-title":"Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial","volume":"25","author":"Gottschalk","year":"2023","journal-title":"Europace"},{"key":"2025081711032916000_11.1.e002423.24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jacc.2021.06.038","article-title":"Cryoballoon ablation as initial treatment for atrial fibrillation: JACC state-of-the-art review","volume":"78","author":"Andrade","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025081711032916000_11.1.e002423.25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa2212540","article-title":"Progression of atrial fibrillation after Cryoablation or drug therapy","volume":"388","author":"Andrade","year":"2023","journal-title":"N Engl J Med"},{"key":"2025081711032916000_11.1.e002423.26","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.amjcard.2018.11.055","article-title":"Meta-analysis of stroke and bleeding risk in patients with various atrial fibrillation patterns receiving oral anticoagulants","volume":"123","author":"Zhang","year":"2019","journal-title":"Am J Cardiol"},{"key":"2025081711032916000_11.1.e002423.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.11.040"},{"key":"2025081711032916000_11.1.e002423.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.519"},{"key":"2025081711032916000_11.1.e002423.29","unstructured":"National Institute for Health and Care Excellence . NICE guideline Ng196: cost-effectiveness analysis J3: ablation. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng196\/evidence\/j3-ablation-costeffectiveness-analysis-pdf-326949243734"},{"key":"2025081711032916000_11.1.e002423.30","doi-asserted-by":"crossref","unstructured":"Rodgers M , McKenna C , Palmer S , et al . n.d. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess;12:34. doi:10.3310\/hta12340","DOI":"10.3310\/hta12340"},{"key":"2025081711032916000_11.1.e002423.31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/europace\/euu188","article-title":"The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for Paroxysmal atrial fibrillation: results from a MANTRA-PAF Substudy","volume":"17","author":"Aronsson","year":"2015","journal-title":"EP Europace"},{"key":"2025081711032916000_11.1.e002423.32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jce.15317","article-title":"Cost\u2010Effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom","volume":"33","author":"Leung","year":"2022","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2025081711032916000_11.1.e002423.33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.hroo.2023.07.007","article-title":"An economic evaluation of first-line Cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of Paroxysmal atrial fibrillation from a U.S Medicare perspective","volume":"4","author":"Wazni","year":"2023","journal-title":"Heart Rhythm O2"},{"key":"2025081711032916000_11.1.e002423.34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCULATIONAHA.122.058575","article-title":"Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: the CABANA randomized clinical trial","volume":"146","author":"Chew","year":"2022","journal-title":"Circulation"},{"key":"2025081711032916000_11.1.e002423.35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jval.2021.10.014","article-title":"Long-term cost-effectiveness comparison of catheter ablation and antiarrhythmic drugs in atrial fibrillation treatment using discrete event simulation","volume":"25","author":"Hu","year":"2022","journal-title":"Value Health"},{"key":"2025081711032916000_11.1.e002423.36","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1062578","article-title":"Cost-effectiveness of rhythm control strategy: ablation versus antiarrhythmic drugs for treating atrial fibrillation in Korea based on real-world data","volume":"10","author":"Kim","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2025081711032916000_11.1.e002423.37","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173979","article-title":"Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients","volume":"10","author":"Sgreccia","year":"2021","journal-title":"J Clin Med"},{"key":"2025081711032916000_11.1.e002423.38","unstructured":"National Health Service . National cost collection for the NHS. 2022. Available: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection"},{"key":"2025081711032916000_11.1.e002423.39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/2396987317746516","article-title":"The economic burden of stroke care in England, Wales and northern Ireland: using a national stroke register to estimate and report patient-level health economic outcomes in stroke","volume":"3","author":"Xu","year":"2018","journal-title":"Eur Stroke J"},{"key":"2025081711032916000_11.1.e002423.40","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1854769"},{"key":"2025081711032916000_11.1.e002423.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2012.00812.x"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2023-002423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T18:03:43Z","timestamp":1755453823000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2023-002423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,18]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/openhrt-2023-002423"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2023-002423","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}